De Novo Heterozygous FBN1 Mutations in the Extreme C‐terminal Region Cause Progeroid Fibrillinopathy
Abhimanyu Garg,Chao Xing
DOI: https://doi.org/10.1002/ajmg.a.36449
2014-01-01
American Journal of Medical Genetics Part A
Abstract:American Journal of Medical Genetics Part AVolume 164, Issue 5 p. 1341-1345 Correspondence De novo heterozygous FBN1 mutations in the extreme C-terminal region cause progeroid fibrillinopathy Abhimanyu Garg, Corresponding Author Abhimanyu Garg Division of Nutrition and Metabolic Diseases, Department of Internal Medicine and the Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, Texas Correspondence to: Abhimanyu Garg, M.D., Chief, Division of Nutrition and Metabolic Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, K5.214, Dallas, TX 75390-8537. E-mail: [email protected]Search for more papers by this authorChao Xing, Chao Xing Department of Clinical Sciences and McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TexasSearch for more papers by this author Abhimanyu Garg, Corresponding Author Abhimanyu Garg Division of Nutrition and Metabolic Diseases, Department of Internal Medicine and the Center for Human Nutrition, University of Texas Southwestern Medical Center, Dallas, Texas Correspondence to: Abhimanyu Garg, M.D., Chief, Division of Nutrition and Metabolic Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, K5.214, Dallas, TX 75390-8537. E-mail: [email protected]Search for more papers by this authorChao Xing, Chao Xing Department of Clinical Sciences and McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TexasSearch for more papers by this author First published: 24 March 2014 https://doi.org/10.1002/ajmg.a.36449Citations: 16Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES Barrett PM, Topol EJ. 2013. The fibrillin-1 gene: Unlocking new therapeutic pathways in cardiovascular disease. Heart 99: 83–90. Detaint D, Faivre L, Collod-Beroud G, Child AH, Loeys BL, Binquet C, Gautier E, Arbustini E, Mayer K, Arslan-Kirchner M, Stheneur C, Halliday D, Beroud C, Bonithon-Kopp C, Claustres M, Plauchu H, Robinson PN, Kiotsekoglou A, De Backer J, Ades L, Francke U, De Paepe A, Boileau C, Jondeau G. 2010. Cardiovascular manifestations in men and women carrying a FBN1 mutation. Eur Heart J 31: 2223–2229. Goldblatt J, Hyatt J, Edwards C, Walpole I. 2011. Further evidence for a marfanoid syndrome with neonatal progeroid features and severe generalized lipodystrophy due to frameshift mutations near the 3′ end of the FBN1 gene. Am J Med Genet A 155A: 717–720. Graul-Neumann LM, Kienitz T, Robinson PN, Baasanjav S, Karow B, Gillessen-Kaesbach G, Fahsold R, Schmidt H, Hoffmann K, Passarge E. 2010. Marfan syndrome with neonatal progeroid syndrome-like lipodystrophy associated with a novel frameshift mutation at the 3′ terminus of the FBN1-gene. Am J Med Genet A 152A: 2749–2755. Horn D, Robinson PN. 2011. Progeroid facial features and lipodystrophy associated with a novel splice site mutation in the final intron of the FBN1 gene. Am J Med Genet A 155A: 721–724. Jensen SA, Robertson IB, Handford PA. 2012. Dissecting the fibrillin microfibril: Structural insights into organization and function. Structure 20: 215–225. Margraf RL, Krautscheid PMF, Pattison DC, Voelkerding KV, Mao R. 2012. Novel p.C620L RET mutation detected in a patient with medullary thyroid carcinoma. Int J Clin Med 3: 498–501. O'Neill B, Simha V, Kotha V, Garg A. 2007. Body fat distribution and metabolic variables in patients with neonatal progeroid syndrome. Am J Med Genet A 143: 1421–1430. Rump P, Letteboer TG, Gille JJ, Torringa MJ, Baerts W, van Gestel JP, Verheij JB, van Essen AJ. 2006. Severe complications in a child with achondroplasia and two FGFR3 mutations on the same allele. Am J Med Genet A 140: 284–290. Takenouchi T, Hida M, Sakamoto Y, Torii C, Kosaki R, Takahashi T, Kosaki K. 2013. Severe congenital lipodystrophy and a progeroid appearance: Mutation in the penultimate exon of FBN1 causing a recognizable phenotype. Am J Med Genet A 161: 3057–3062. Tessitore A, Sinisi AA, Pasquali D, Cardone M, Vitale D, Bellastella A, Colantuoni V. 1999. A novel case of multiple endocrine neoplasia type 2A associated with two de novo mutations of the RET protooncogene. J Clin Endocrinol Metab 84: 3522–3527. Citing Literature Volume164, Issue5May 2014Pages 1341-1345 ReferencesRelatedInformation